• 1
    Cannistra SA. Cancer of the ovary. N Engl J Med. 2004; 351: 2519-2529.
  • 2
    Buys SS, Partridge E, Greene MH, et al. Ovarian cancer screening in the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial: findings from the initial screen of a randomized trial. Am J Obstet Gynecol. 2005; 193: 1630-1639.
  • 3
    Kim G, Minig L, Kohn EC. Proteomic profiling in ovarian cancer. Int J Gynecol Cancer. 2009; 19: S2-S6.
  • 4
    Zhang Z, Bast RC Jr, Yu Y, et al. Three biomarkers identified detection of early stage ovarian cancer. Cancer Res. 2004; 64: 5882-5890.
  • 5
    Hodgall E, Fung ET, Zhang Z, et al. Prospective independent validation of a marker panel for distinguishing malignant from benign pelvic masses: proceedings of the 39th Annual Meeting of the Society of Gynecologic Oncologists [abstract]. Gynecol Oncol. 2008; 108( suppl 2).
  • 6
    Moore LE, Fung ET, McGuire M, et al. Evaluation of apolipoprotein A1 and postranslationally modified forms of transthyretin as biomarkers for ovarian cancer detection in an independent study population. Cancer Epidemiol Biomarkers Prev. 2006; 15: 1641-1646.
  • 7
    Clarke CH, Fung ET, Yip C, et al. Use of a panel of proteomic markers to improve the sensitivity of CA125 for detecting stage I epithelial ovarian cancer [abstract]. J Clin Oncol. 2008; 26( May 20 suppl). Abstract 5542.
  • 8
    Zhu CS, Pinsky PF, Cramer DW, et al; for the PLCO Project Team. A framework for evaluating biomarkers for early detection: validation of biomarker panels for ovarian cancer. Cancer Prev Res. 2011; 4: 375-383.
  • 9
    Cramer DW, Bast RC Jr, Berg CD, et al. Ovarian cancer biomarker performance in Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial specimens. Cancer Prev Res. 2011; 4: 365-374.
  • 10
    Fung ET, Yip TT, Lomas L, et al. Classification of cancer types by measuring variants of host response proteins using SELDI serum assays, Int J Cancer. 2005; 115: 783-789.
  • 11
    Hand DJ. Discrimination and Classification. NY: John Wiley & Sons, Inc.; 1981.
  • 12
    SAS Institute, Inc. SAS Users Guide, Version 9. Cary, NC: SAS Institute, Inc.; 1999.
  • 13
    Breiman L, Spector P. Submodel selection and evaluation in regression. The X-random case. Int Stat Rev. 1992; 60: 291-319.
  • 14
    Fisher RA. The use of multiple measurements in taxonomic problems. Ann Eugenics. 1950; 1936: 179-188.
  • 15
    Bast RC Jr, Klug TL, St John E, et al. A radioimmunoassay using a monoclonal antibody to monitor the course of epithelial ovarian cancer. N Engl J Med. 1983; 309: 883-887.
  • 16
    Bast RC Jr, Siegal FP, Runowicz C, et al. Elevation of serum CA125 prior to diagnosis of an epithelial ovarian carcinoma. Gynecol Oncol. 1985; 22: 115-120.
  • 17
    Skates SJ, Xu FJ, Yu YH, et al. Toward an optimal algorithm for ovarian cancer screening with longitudinal tumor markers. Cancer. 1995; 76( 10 suppl): 2004-2010.
  • 18
    Menon U, Gentry-Maharaj A, Hallett R, et al. Sensitivity and specificity of multimodal and ultrasound screening for ovarian cancer, and stage distribution of detected cancers: results of the prevalence screen of the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS). Lancet Oncol. 2009; 10: 327-340.
  • 19
    Lu KH, Skates S, Bevers T, et al. A prospective US ovarian cancer screening study using the risk of ovarian cancer algorithm (ROCA) [abstract]. Proc Am Soc Clin Oncol. 2010; 28: 390s. Abstract 5003.
  • 20
    Yurkovetsky Z, Lomakin A, Skates S, et al. Development of a multimarker assay for early detection of ovarian cancer. J Clin Oncol. 2010; 28: 2159-2166.